[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592181":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":28,"responsibleParty":96,"collaborators":20,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":20,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":20,"enrollmentInfo":107,"targetDuration":20,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":20,"overallStatus":56,"whyStopped":20,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Hannover Medical School","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Study participants receive complete or partially HLA-matched, allogeneic HPyV-2-specific T-lymphocytes",[13],"Drug: Application of T-lymphocytes",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Application of T-lymphocytes","Dosage form: Infusion; Route of administration: Intravenous; Cell dose: 1-2 x 10.000 viable CD3+ T-lymphocytes per kg bodyweight; Application at three timepoints: baseline, after two weeks, after 6 weeks",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Thomas Skripuletz, Prof. Dr.","CONTACT","+49 511 532","3120","skripuletz.thomas@mh-hannover.de",[29,46,55,67,77,86],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"LMU Klinikum Campus Großhadern","NOT_YET_RECRUITING","München","Bavaria","81377","Germany","DE",{"type":38,"coordinates":39},"Point",[40,41],13.46314,48.69668,{"lat":41,"lon":40},[44],{"name":45,"role":24,"phone":20,"phoneExt":20,"email":20},"Franziska Hopfner, Prof. Dr.",{"facility":47,"status":31,"city":48,"state":49,"zip":20,"country":35,"countryCode":36,"cosmosGeoPoint":50,"geoPoint":54,"contacts":20},"Universitätsklinikum Marburg","Marburg","Hesse",{"type":38,"coordinates":51},[52,53],8.77069,50.80904,{"lat":53,"lon":52},{"facility":5,"status":56,"city":57,"state":58,"zip":59,"country":35,"countryCode":36,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"RECRUITING","Hanover","Lower Saxony","30625",{"type":38,"coordinates":61},[62,63],9.73322,52.37052,{"lat":63,"lon":62},[66],{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"facility":68,"status":31,"city":69,"state":70,"zip":71,"country":35,"countryCode":36,"cosmosGeoPoint":72,"geoPoint":76,"contacts":20},"Universitätsklinikum Düsseldorf","Düsseldorf","North Rhine-Westphalia","40225",{"type":38,"coordinates":73},[74,75],6.77927,51.22319,{"lat":75,"lon":74},{"facility":78,"status":31,"city":79,"state":70,"zip":80,"country":35,"countryCode":36,"cosmosGeoPoint":81,"geoPoint":85,"contacts":20},"Universitätsklinikum Essen","Essen","45147",{"type":38,"coordinates":82},[83,84],7.01228,51.45657,{"lat":84,"lon":83},{"facility":87,"status":31,"city":88,"state":89,"zip":90,"country":35,"countryCode":36,"cosmosGeoPoint":91,"geoPoint":95,"contacts":20},"Universitätsklinikum Schleswig-Holstein","Kiel","Schleswig-Holstein","24105",{"type":38,"coordinates":92},[93,94],10.13489,54.32133,{"lat":94,"lon":93},{"type":97,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100592181","phase-2-t-cell-therapy-in-patients-with-pml-100592181",false,"NCT06990087","T-cell Therapy in Patients With PML","CurePML - Allogeneic HPyV-2-specific T-cell Therapy in Patients With Progressive Multifocal Leukoencephalopathy","Inclusion Criteria:\n\n* Adults\\* aged ≥ 18 years with PML (diagnosed ≤ 60 days before screening) associated with one or more of the following risk factors: lymphoproliferative diseases, immunosuppressive therapy, or lymphopenia\n* Signed written informed consent from subject and\u002For legal representative\n* HPyV-2 detection in CSF by PCR analysis or in brain biopsy\n\nExclusion Criteria:\n\n* PML caused by HIV\n* PML caused by natalizumab\n* PML occurring within five 5 years after hematopoietic stem-cell transplantation or CAR T cell therapy, or resulting from chronic lymphocytic leukemia (CLL)\n* Patients who are unable to follow the study protocol, either on their own or with the support of a reliable representative, will be excluded\n* Pregnancy or breastfeeding\n* Currently receiving chemotherapy\n* Present (within 2 weeks before screening visit) and continuous treatment with immune checkpoint inhibition therapy\n* Severe infections other than PML (e.g. sepsis, pneumonia)\n* Hypersensitivity to any of the components of the medications used\n* Inability to undergo MRI examination (e.g. implanted incompatible medical devices, claustrophobia)\n* Participation in another clinical trial (other investigational drugs or devices at the time of enrolment or within 30 days prior to enrolment)","ALL","18 Years",{"count":108,"type":109},23,"ESTIMATED","INTERVENTIONAL",[112],"PHASE2","There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study. The sponsor wants to find out whether the IMP is safe, influences the neurological status and improves the quality of the life of patients . It is to be investigated whether the IMP can be used to treat the disease and whether it could have an advantage over the standard therapy in terms of survival rate.",[115],"Progressive Multifocal Leucoencephalopathy (PML)","2026-02-10",{"date":118,"type":119},"2026-02-12","ACTUAL",{"date":121,"type":119},"2026-02-06",{"date":123,"type":109},"2027-11",{"name":5,"class":6},6]